CN Patent

CN121889396A — 用于治疗甲状腺眼病的林西替尼的结晶盐

Assigned to Siling Treatment Co · Expires 2026-04-17 · 0y expired

What this patent protects

本发明提供了林西替尼(OSI‑906；顺式‑3‑[8‑氨基‑1‑(2‑苯基‑7‑喹啉基)咪唑并[1,5‑ a ]吡嗪‑3‑基]‑1‑甲基‑环丁醇)的新颖的盐和结晶形式。这些新形式的林西替尼为口服施用的药物制剂提供了增加的溶解度和改进的药代动力学概况。因此，本发明使得能够实现用于治疗人类胰岛素样生长因子‑1受体(IGF‑1R)和胰岛素受体(IR)介导的状况的改进的方法。

USPTO Abstract

本发明提供了林西替尼(OSI‑906；顺式‑3‑[8‑氨基‑1‑(2‑苯基‑7‑喹啉基)咪唑并[1,5‑ a ]吡嗪‑3‑基]‑1‑甲基‑环丁醇)的新颖的盐和结晶形式。这些新形式的林西替尼为口服施用的药物制剂提供了增加的溶解度和改进的药代动力学概况。因此，本发明使得能够实现用于治疗人类胰岛素样生长因子‑1受体(IGF‑1R)和胰岛素受体(IR)介导的状况的改进的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN121889396A
Jurisdiction: CN
Classification: —
Expires: 2026-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Siling Treatment Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.